Please assess the completion status of the following clinical trial:

Trial Title: Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must have a primary diagnosis of ADHD~* Subject must be adequately controlled on a stable dose of one of the following medications for a 30 day period: Ritalin LA(r), Concerta(r), or Metadate DC(r), not to exceed 54 mg per day~* Females of childbearing potential must have a negative serum beta Human Chorionic Gonadotropin pregnancy test~Exclusion Criteria:~* A history of mental retardation that would indicate that the subject is not functioning at an age appropriate level intellectually~* A recent history of suspected substance abuse or dependence disorder~* Subject is taking Strattera~* Clinical signs and symptoms of skin irritation or hyper/hypopigmentation at the potential application sites

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Methylphenidate Transdermal System (Type: ACTIVE_COMPARATOR): Methylphenidate 27.5mg, 41.3mg, 55mg, and 82.5mg patches applied daily for 8 weeks
- Placebo patch (Type: PLACEBO_COMPARATOR): Placebo patch applied daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).